Clinical Scorecard: What Causes the Itch in Dermatitis?

At a Glance

Key Highlights

• IL-33 acts as an 'alarmin' signaling tissue injury and promoting type 2 immune response.
• IL-31 directly stimulates itch-sensing nerve fibers and worsens skin barrier function.
• The IL-31/IL-33 axis creates a self-perpetuating itch-scratch cycle.
• Higher levels of IL-31 and IL-33 correlate with disease severity.
• Targeted therapies may disrupt the IL-31/IL-33 signaling pathway.

Guideline-Based Recommendations

Diagnosis

• Assess clinical history and symptoms of itching and skin lesions.
• Consider measuring IL-31 and IL-33 levels for severity tracking.

Management

• Implement topical treatments to restore skin barrier function.
• Consider newer targeted therapies that inhibit IL-31 and IL-33.

Monitoring & Follow-up

• Regularly evaluate itch severity and skin condition.
• Monitor IL-31 and IL-33 levels to assess treatment response.

Risks

• Increased risk of skin infections due to scratching.
• Potential for chronic sleep disturbances from relentless itching.

Patient & Prescribing Data

Individuals diagnosed with atopic dermatitis, particularly those with severe itching.

Targeted therapies focusing on the IL-31/IL-33 axis may provide relief from itching.

Clinical Best Practices

• Educate patients on the importance of avoiding scratching.
• Encourage the use of moisturizers to maintain skin barrier integrity.
• Consider referral to specialists for severe cases or treatment-resistant dermatitis.

References

• International Journal of Molecular Sciences